MYB and CD4+/CD56+ hematodermic neoplasm: Given the higher frequency of MYB alterations in pediatric BPDCN, screening for MYB rearrangements, including via RNA sequencing, should be considered in the diagnostic workup of pediatric BPDCN, as it may have implications for risk stratification and the development of future targeted therapies.